Business Context and Reporting Period
This Form 8-K filing by Theriva Biologics, Inc. (TOVX) covers the date of December 15, 2025. The report addresses a failed Special Meeting of Stockholders intended to seek approval for the issuance of common stock upon the exercise of new warrants.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes and Events
- Failed Special Meeting: On December 15, 2025, the Company called a Special Meeting of Stockholders but failed to achieve a quorum due to insufficient shares present or represented by proxy.
- Warrant Inducement Agreement: The meeting was convened to seek stockholder approval for the issuance of up to 16,184,560 shares of common stock upon the exercise of "New Warrants" issued under an Inducement Agreement dated October 16, 2025.
- Recurring Meeting Obligation: Due to the failure to convene the meeting, the Company is contractually obligated to call an additional stockholder meeting every 60 days until stockholder approval is obtained or the New Warrants are no longer outstanding.
Guidance, Outlook, and Risks
The Company has determined to call a new special meeting to seek approval of the warrant exercise proposal and adjournment proposal. The date and time of this new meeting will be announced subsequently, along with the filing and mailing of required proxy materials. The primary risk identified is the ongoing inability to secure stockholder approval, which triggers a recurring 60-day meeting cycle.
Investor Verification Checklist
- Verify the date and time of the newly scheduled Special Meeting of Stockholders.
- Review the proxy materials for the upcoming meeting to understand the specific terms of the warrant exercise proposal.
- Monitor the status of the 16,184,560 shares of common stock subject to the New Warrants and the associated Inducement Agreement.
- Assess the Company's ability to achieve a quorum in future meetings to avoid indefinite 60-day meeting cycles.